Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease

详细信息    查看全文

• 作者：Maria Fleseriu ; Rosario Pivonello ; Jacques Young ; Amir H. Hamrahian…
• 关键词：LCI699 ; Osilodrostat ; 11β ; hydroxylase ; Cushing’s ; Cortisol
• 刊名：Pituitary
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：19
• 期：2
• 页码：138-148
• 全文大小：900 KB
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Diabetes
  Neurosurgery
  
• 出版者：Springer Netherlands
• ISSN：1573-7403

文摘

Purpose In a 10-week proof-of-concept study (LINC 1), the potent oral 11β-hydroxylase inhibitor osilodrostat (LCI699) normalized urinary free cortisol (UFC) in 11/12 patients with Cushing’s disease. The current 22-week study (LINC 2; NCT01331239) further evaluated osilodrostat in patients with Cushing’s disease.